Cargando…

Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort

OBJECTIVE: Benefits and risks of new therapies in Multiple Sclerosis (MS) must be balanced carefully and tailored to patients. We aimed to describe our experience with Fingolimod (FTY), correlating demographics, clinical and hematological features of the Relapsing MS (RMS) cohort with the occurring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manni, Alessia, Direnzo, Vita, Iaffaldano, Antonio, Di Lecce, Valentina, Tortorella, Carla, Zoccolella, Stefano, Iaffaldano, Pietro, Trojano, Maria, Paolicelli, Damiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651388/ https://www.ncbi.nlm.nih.gov/pubmed/29075564 http://dx.doi.org/10.1002/brb3.804

Ejemplares similares

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients
por: Zoccolella, Stefano, et al.
Publicado: (2012)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
por: Paolicelli, Damiano, et al.
Publicado: (2022)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
por: Manni, Alessia, et al.
Publicado: (2019)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
por: Ruggieri, Maddalena, et al.
Publicado: (2020)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients
por: Biasi, Madia M., et al.
Publicado: (2023)

Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience
por: Guerra, Tommaso, et al.
Publicado: (2022)

Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue
por: Paolicelli, Damiano, et al.
Publicado: (2021)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration
por: Liguori, Maria, et al.
Publicado: (2014)

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
por: Trojano, Maria, et al.
Publicado: (2012)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
por: Druart, Charlotte, et al.
Publicado: (2017)

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
por: Iaffaldano, Pietro, et al.
Publicado: (2021)

Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial
por: Simone, Marta, et al.
Publicado: (2018)

A rare association between multiple sclerosis and Charcot‐Marie‐Tooth type 1B
por: Cortese, Rosa, et al.
Publicado: (2016)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis
por: Simone, Marta, et al.
Publicado: (2021)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
por: Portaccio, Emilio
Publicado: (2011)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
por: Song, Zi-Ye, et al.
Publicado: (2015)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
por: Hunter, Samuel F., et al.
Publicado: (2015)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
por: Prosperini, Luca, et al.
Publicado: (2019)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a973pjc7aalutl06nla6he5fv2